<DOC>
	<DOC>NCT02235545</DOC>
	<brief_summary>The purpose of this post approval study is to characterize the chronic performance of the SJM Optisure family of HV leads in patients.</brief_summary>
	<brief_title>Optisure Lead Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia, Ventricular</mesh_term>
	<criteria>Eligible patients will meet all of the following: 1. Have an approved indication, as per ACC/AHA/HRS/ESC guidelines, for implantation of an ICD or CRTD system for treatment of heart failure or lifethreatening ventricular tachyarrhythmia(s). 2. Have been implanted with a St. Jude Medical Optisure lead in the last 30 days or are scheduled for an Optisure lead implant. 3. Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed followup tests and schedule of evaluations. 4. Are 18 years or above, or of legal age to give informed consent specific to state and national law. Patients will be excluded if they meet any of the following: 1. Enrolled or intend to participate in a clinical drug and/or device study, which could confound the results of this trial as determined by SJM, during the course of this clinical study. 2. Have a life expectancy of less than 5 years due to any condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HV Lead</keyword>
	<keyword>ICD</keyword>
	<keyword>CRT-D System</keyword>
	<keyword>Treatment of Heart Failure</keyword>
	<keyword>Treamtent of life-threatening ventricular tachyarrhythmia</keyword>
	<keyword>Optisure</keyword>
</DOC>